Managing Growth Hormone Deficiency Across the Continuum of Care - Episode 13
Dosing and Managing Long-Acting GH Therapy in Adults — Clinical Factors, Titration, and Side Effects
Clinicians explain practical weekly growth hormone dosing—weight-based, pen-device rounding, and IGF‑1 checks—plus how puberty, fatigue, and growth velocity guide stopping therapy.
This episode examines adult-specific dosing and management strategies for long-acting GH analogs, with attention to clinical factors that guide formulation selection, titration targets, and the management of side effects more common in adults than children.
Dr. Garcia and Dr. Agrawal outline their approach to selecting between daily and weekly GH in adult patients. In an ideal world, patient preference and adherence would be the primary drivers. Dr. Garcia describes a patient in law enforcement who could not carry needles into a correctional facility — making weekly GH not just preferred but functionally necessary. Dr. Agrawal states she would switch all appropriate adult patients to weekly formulations if insurance access allowed, given the convenience and adherence benefits.
Adult dosing for long-acting analogs is non-weight-based and age-stratified. For somapacitan, the standard adult starting dose is 1.5 mg/week, though clinicians typically initiate lower (e.g., 1 mg/week) and titrate up. Elderly patients (>60–70 years) and those with poorly controlled type 2 diabetes start even lower. Women on oral estrogen (birth control pills) — due to hepatic GH resistance — may require a higher starting dose (2 mg/week). For lonapegsomatropin, dosing tiers of 0.7, 1.4, and 2.1 mg/week are adjusted based on patient age, sex hormone use, and comorbidities.
IGF-1 monitoring in adults should occur at mid-week (day 3–4 for somapacitan; day 4–5 for lonapegsomatropin) to capture the pharmacokinetic midpoint. Target IGF-1 is 0 to +2 standard deviation score above the mean. However, adults frequently experience side effects — particularly edema, arthralgias, and carpal tunnel symptoms — that limit dose escalation before the IGF-1 target is reached.
Dr. Garcia emphasizes the need to assess baseline joint symptoms before initiating GH, since arthralgia is the most common adult side effect and often indistinguishable from pre-existing musculoskeletal complaints.
In the next episode, “Transitioning GHD Patients from Pediatric to Adult Care — Challenges and Best Practices,” the panel addresses one of the most clinically challenging aspects of GHD management: navigating the handoff from pediatric to adult endocrinology and preventing loss to follow-up.
